In the third quarter, 4SC also progressed with preparations for a Phase I/II research of resminostat as a second-line therapy in colon cancer patients with K-ras mutations. This scholarly study is scheduled to start prior to the end of 2010. 4SC also produced progress in its other oncology programmes during the third one fourth. The Phase I study of 4SC-203, a multi-target kinase inhibitor, was completed in healthy volunteers and the evaluation of results is scheduled for the fourth quarter of this year. The Stage I research of the Eg5 inhibitor 4SC-205 also progressed according to strategy in the third quarter. Another concentrate in the third one fourth was on the further development of the second HDAC inhibitor, 4SC-202. Pending authorization from all regulatory authorities, a Phase I medical study in hematological tumours will commence this season to check this drug candidate, which has a target profile that differs considerably from that of resminostat .‘In a conference contact with reporters, AMA President J. James Rohack, a doctor, accused Senators of turning their backs on seniors and ‘leaving for vacation’ without coping with the payment issue. He also said armed service families will be affected because doctor rates for TRICARE, the military medical health insurance strategy, are tied to Medicare. This article is certainly republished with kind authorization from our friends at The Kaiser Family Foundation. You will see the entire Kaiser Daily Health Plan Survey, search the archives, or join email delivery of in-depth coverage of health policy developments, debates and discussions. The Daily Health Plan Report is published for Kaisernetwork.org, a free support of The Henry J.